World Cancer Immunotherapy Market Examined by Kuick Research in Its Topical Report Available at MarketPublishers.com

12 May 2017 • by Natalie Aster

LONDON – To date, over 2000 cancer immunotherapies based drugs/therapies are currently in clinical development. Most of these are in pre-clinical phase, Phase-I and II trials. 14 cancer vaccines, 44 cancer monoclonal antibodies (mAbs), 3 oncology cell therapies and 61 immunomodulators for cancer treatment are marketed today.

Pharmacos are focused on active R&D of cancer immunotherapies with higher safety and efficacy profiles owing to the presence of a large number of unmet medical needs. Increased investments in the R&D segment could considerably boost the rates of drug discovery, which will likely ease the medical status of cancer patients. At the same time, technological advances are projected to spur the development of worthy candidates with high pharmacological and commercialisation potential in the offing.

Cancer immunotherapies have been used for a restricted number of malignancies versus other drug categories. Mostly hematological cancers such as follicular lymphoma, chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) have remained the central focus area. Other indications like NSCLC, melanoma, RCC and prostate cancer have also got cancer immunotherapeutic agents.

Cancer incidence rates are gaining rapid traction, with cancer immunetherapeutics likely to play an essential role in delivering enhanced medical care to patients. Some of them have obtained FDA’s accelerated approval and breakthrough therapy (BT) designation owing to their top-notch pharmacological benefits. Similar progress is expected to be shown by cancer immunotherapeutic agents in the pipeline for various malignancies.

Topical research report “Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022” elaborated by Kuick Research gives comprehensive insights into clinical and non-clinical developments in the cancer immunotherapy domain.

The study investigates the evolution of canter immunotherapy, offers categorisation of cancer immunotherapy, covers the fundamentals of cancer vaccines, gives information on the new era of monoclonal antibodies, explores trails of T-cell therapies, discusses the aspects of immune checkpoint inhibitors, etc. Key economic aspects of cancer immunotherapy and cancer immunotherapy cost by product are provided. The report examines the market aspects of cancer immunotherapy limelighting present-day market trends and reviewing the cancer immunotherapy pipeline. It explores market dynamics covering drivers and challenges; gives detailed clinical trials and development insight; presents an overview of the global cancer immunotherapy pipeline; analyses the marketed cancer immunotherapy by class; speculates on the future development of the global cancer immunotherapy marketplace. Furthermore, the report explores the competitive analysis and profiles the top 30 market players.

More topical studies by Kuick Research can be found at its page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com